Oxidative Stress: Dual Pathway Induction in Cardiorenal Syndrome Type 1 Pathogenesis

Table 2

Medication of CRS Type 1 and AHF patients.

	AHF	CRS Type 1	value
Angiotensin-converting-enzyme inhibitor (ACEi)	58%	55%	NS
Angiotensin II receptor blockers (ARB)	17%	18%	NS
β-blocker	66%	63%	NS
Calcium antagonist	25%	27%	NS
Diuretics	92%	100%	NS
Statines	50%	55%	NS
Nonsteroidal anti-inflammatory drugs (NSAIDs)	8%	9%	NS